Show simple item record

dc.contributor.authorMoynihan, Cen_US
dc.contributor.authorBancroft, EKen_US
dc.contributor.authorMitra, Aen_US
dc.contributor.authorArdern-Jones, Aen_US
dc.contributor.authorCastro, Een_US
dc.contributor.authorPage, ECen_US
dc.contributor.authorEeles, RAen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-01-17T15:24:04Z
dc.date.issued2017-11en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28812325en_US
dc.identifier.citationPsychooncology, 2017, 26 (11), pp. 1987 - 1993en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1002
dc.identifier.eissn1099-1611en_US
dc.identifier.doi10.1002/pon.4530en_US
dc.description.abstractOBJECTIVE: Increased risk of prostate cancer (PCa) is observed in men with BRCA1/BRCA2 mutations. Sex and gender are key determinants of health and disease although unequal care exists between the sexes. Stereotypical male attitudes are shown to lead to poor health outcomes. METHODS: Men with BRCA1/2 mutations and diagnosed with PCa were identified and invited to participate in a qualitative interview study. Data were analysed using a framework approach. "Masculinity theory" was used to report the impact of having both a BRCA1/2 mutation and PCa. RESULTS: Eleven of 15 eligible men were interviewed. The umbrella concept of "Ambiguity in a Masculine World" was evident. Men's responses often matched those of women in a genetic context. Men's BRCA experience was described, as "on the back burner" but "a bonus" enabling familial detection and early diagnosis of PCa. Embodiment of PCa took precedence as men revealed stereotypical "ideal" masculine responses such as stoicism and control while creating new "masculinities" when faced with the vicissitudes of having 2 gendered conditions. CONCLUSION: Health workers are urged to take a reflexive approach, void of masculine ideals, a belief in which obfuscates men's experience. Research is required regarding men's support needs in the name of equality of care.en_US
dc.format.extent1987 - 1993en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectBRCA1en_US
dc.subjectBRCA2en_US
dc.subjectgender/masculinityen_US
dc.subjectprostate canceren_US
dc.subjectpsychosocialen_US
dc.subjectAdulten_US
dc.subjectGenes, BRCA1en_US
dc.subjectGenes, BRCA2en_US
dc.subjectGenetic Predisposition to Diseaseen_US
dc.subjectHumansen_US
dc.subjectInterviews as Topicen_US
dc.subjectMaleen_US
dc.subjectMasculinityen_US
dc.subjectMenen_US
dc.subjectMiddle Ageden_US
dc.subjectMutationen_US
dc.subjectProstateen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectQualitative Researchen_US
dc.subjectSexual Behavioren_US
dc.titleAmbiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-08-08en_US
rioxxterms.versionofrecord10.1002/pon.4530en_US
rioxxterms.licenseref.startdate2017-11en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfPsychooncologyen_US
pubs.issue11en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume26en_US
pubs.embargo.termsNot knownen_US
icr.researchteamOncogeneticsen_US
dc.contributor.icrauthorEeles, Rosalinden_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record